Immutep Future Growth
Future criteria checks 2/6
Immutep is forecast to grow earnings and revenue by 20% and 57.9% per annum respectively. EPS is expected to grow by 44.2% per annum. Return on equity is forecast to be -68.8% in 3 years.
Key information
20.0%
Earnings growth rate
44.2%
EPS growth rate
Biotechs earnings growth | 24.0% |
Revenue growth rate | 57.9% |
Future return on equity | -68.8% |
Analyst coverage | Good |
Last updated | 03 May 2024 |
Recent future growth updates
No updates
Recent updates
Immutep: Realizing The Expected Catalysts, With More To Come
May 01Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype
Oct 04Immutep secures €1.8M cash in French government's research tax credit
Sep 23Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo
Aug 30Immutep gets Japanese patent related to autoimmune disease drug candidate IMP761
Jul 06Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player
Jun 12Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play
Mar 21Immutep expands the evaluation of efti into a triple combination therapy, shares down 12%
Jun 21Immutep reveals anti-LAG-3 research program
Jun 08Immutep jumps 9% on Chinese patent for efti in chemo-immunotherapy combination
May 26Immutep completes recruitment in efti mid-stage study in head & neck cancer
Jan 07Immutep secures U.S. patent for Eftilagimod Alpha
Dec 29Immutep +72% after breast cancer trial shows promising survival data
Dec 09Immutep to enroll additional patients in mid-stage study with its lead cancer program
Nov 19Immutep rallies on Australian patent grant for IMP701 antibody
Nov 09Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2026 | 166 | 21 | 98 | 61 | 4 |
6/30/2025 | 18 | -43 | -63 | -43 | 5 |
6/30/2024 | 4 | -45 | -47 | -45 | 6 |
12/31/2023 | 4 | -41 | -42 | -42 | N/A |
9/30/2023 | 4 | -40 | -39 | -39 | N/A |
6/30/2023 | 4 | -40 | -35 | -35 | N/A |
3/31/2023 | 4 | -38 | -33 | -33 | N/A |
12/31/2022 | 4 | -37 | -30 | -30 | N/A |
9/30/2022 | 5 | -34 | -30 | -30 | N/A |
6/30/2022 | 5 | -32 | -30 | -30 | N/A |
3/31/2022 | 4 | -29 | -25 | -25 | N/A |
12/31/2021 | 4 | -26 | -20 | -20 | N/A |
9/30/2021 | 4 | -28 | -19 | -19 | N/A |
6/30/2021 | 4 | -30 | -18 | -18 | N/A |
3/31/2021 | 5 | -29 | -16 | -16 | N/A |
12/31/2020 | 6 | -27 | -15 | -15 | N/A |
9/30/2020 | 10 | -20 | -13 | -13 | N/A |
6/30/2020 | 14 | -13 | -11 | -11 | N/A |
3/31/2020 | 13 | -15 | -13 | -13 | N/A |
12/31/2019 | 13 | -16 | -14 | -14 | N/A |
9/30/2019 | 9 | -17 | -15 | -15 | N/A |
6/30/2019 | 6 | -18 | -15 | -15 | N/A |
3/31/2019 | 5 | -18 | -13 | -13 | N/A |
12/31/2018 | 5 | -17 | -10 | -10 | N/A |
9/30/2018 | 6 | -15 | -9 | -9 | N/A |
6/30/2018 | 7 | -13 | -8 | -8 | N/A |
3/31/2018 | 6 | -12 | -8 | -8 | N/A |
12/31/2017 | 7 | -10 | -8 | -8 | N/A |
9/30/2017 | 5 | -9 | N/A | -8 | N/A |
6/30/2017 | 4 | -9 | N/A | -9 | N/A |
3/31/2017 | 3 | -10 | N/A | -8 | N/A |
12/31/2016 | 2 | -10 | N/A | -9 | N/A |
9/30/2016 | 2 | -36 | N/A | -10 | N/A |
6/30/2016 | 2 | -62 | N/A | -11 | N/A |
3/31/2016 | 2 | -71 | N/A | -10 | N/A |
12/31/2015 | 1 | -82 | N/A | -8 | N/A |
9/30/2015 | 1 | -57 | N/A | -8 | N/A |
6/30/2015 | 1 | -32 | N/A | -8 | N/A |
3/31/2015 | 1 | -23 | N/A | -10 | N/A |
12/31/2014 | 1 | -14 | N/A | -13 | N/A |
9/30/2014 | 2 | -14 | N/A | -13 | N/A |
6/30/2014 | 2 | -13 | N/A | -14 | N/A |
3/31/2014 | 2 | -13 | N/A | -14 | N/A |
12/31/2013 | 2 | -13 | N/A | -14 | N/A |
9/30/2013 | 2 | -14 | N/A | -15 | N/A |
6/30/2013 | 2 | -15 | N/A | -16 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMMP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMMP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMMP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMMP's revenue (57.9% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: IMMP's revenue (57.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IMMP is forecast to be unprofitable in 3 years.